Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

YERVOY 5 mg/ml concentrate for solution for infusion

Active Ingredient:
ipilimumab
Company:  
Bristol Myers Squibb Pharmaceuticals limited See contact details
ATC code: 
L01FX04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Product Information HCP Med Info
{arrow_left}
{arrow_right}
Information for Healthcare Professionals (HCPs): Yervoy (ipilimumab) HCP Guide (Risk Minimisation Material)
*Retirement*

The ipilimumab HCP Guide (Title: Risk Minimisation Information for Healthcare Professionals Guide for Prescribing, version August 2018 731UK1800900-03) has been retired as an ipilimumab risk minimisation material. The digital platform for the Yervoy HCP Risk Minimisation Information for Healthcare Professionals Guide for Prescribing has also been retired as part of this update.


Information for Patients and Healthcare Professionals: Yervoy (ipilimumab) Patient Risk Minimisation Website *Retirement*

The digital platform for the Yervoy Patient Information Guide has been retired. Please note that the paper/PDF copies of the Yervoy Patient Information Guide and Patient Alert Card are still available.
Bristol Myers Squibb Pharmaceuticals limited
Company image
Address
Bristol-Myers Squibb, ARC Uxbridge, Sanderson Road, New Denham, Denham, Buckinghamshire, UB8 1DH, UK
Telephone
+44 (0)1895 523 000
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0) 800 731 1736
Medical Information Website
https://www.bmsmedinfo.co.uk/